MHC associations with clinical and autoantibody manifestations in European SLE by Morris, D L et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/gene.2014.6
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Morris, D. L., Fernando, M. M. A., Taylor, K. E., Chung, S. A., Nititham, J., Alarcon-Riquelme, M. E., ... Criswell,
L. A. (2014). MHC associations with clinical and autoantibody manifestations in European SLE. GENES AND
IMMUNITY, 15(4), 210-217. 10.1038/gene.2014.6
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
OPEN
ORIGINAL ARTICLE
MHC associations with clinical and autoantibody manifestations
in European SLE
DL Morris1, MMA Fernando1,17, KE Taylor2,17, SA Chung2, J Nititham2, ME Alarco´n-Riquelme3,4, LF Barcellos5, TW Behrens6, C Cotsapas7,
PM Gaffney4, RR Graham6, BA Pons-Estel8, PK Gregersen9, JB Harley10, SL Hauser11, G Hom6, CD Langefeld12, JA Noble13, JD Rioux14,
MF Seldin15, Systemic Lupus Erythematosus Genetics Consortium16, TJ Vyse1 and LA Criswell2
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease affecting multiple organ systems and characterized by
autoantibody formation to nuclear components. Although genetic variation within the major histocompatibility complex (MHC) is
associated with SLE, its role in the development of clinical manifestations and autoantibody production is not well deﬁned. We
conducted a meta-analysis of four independent European SLE case collections for associations between SLE sub-phenotypes and
MHC single-nucleotide polymorphism genotypes, human leukocyte antigen (HLA) alleles and variant HLA amino acids. Of the 11
American College of Rheumatology criteria and 7 autoantibody sub-phenotypes examined, anti-Ro/SSA and anti-La/SSB antibody
subsets exhibited the highest number and most statistically signiﬁcant associations. HLA-DRB1*03:01 was signiﬁcantly associated
with both sub-phenotypes. We found evidence of associations independent of MHC class II variants in the anti-Ro subset alone.
Conditional analyses showed that anti-Ro and anti-La subsets are independently associated with HLA-DRB1*0301, and that the HLA-
DRB1*03:01 association with SLE is largely but not completely driven by the association of this allele with these sub-phenotypes.
Our results provide strong evidence for a multilevel risk model for HLA-DRB1*03:01 in SLE, where the association with anti-Ro and
anti-La antibody-positive SLE is much stronger than SLE without these autoantibodies.
Genes and Immunity advance online publication, 6 March 2014; doi:10.1038/gene.2014.6
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INTRODUCTION
Systemic lupus erythematosus (SLE; OMIM 152700) is a
complex autoimmune disease that can affect multiple organ
systems. Processes involving both the innate and adaptive
immune systems contribute to its development.1 The
disease is clinically heterogeneous, and affected individuals
only need 4 out of 11 of the American College of Rheumato-
logy (ACR) criteria to be classiﬁed as having SLE. Although
patients may differ in their clinical manifestations, patients
do share a propensity to develop autoantibodies directed
against nucleic acids and associated nuclear and cellular
proteins.
There is overwhelming evidence of a genetic component to
SLE risk with higher concordance rates observed between
monozygotic twins (20–40%) compared with dizygotic twins
(2–5%).2 The familial aggregation for SLE (sibling risk ratio,
ls¼ 8–29)2,3 is higher than other autoimmune diseases, and
the estimate of heritability is approximately 66%.4 Genetic
association studies of SLE have been successful in identifying
multiple loci.5–11 However, relatively few studies have investigated
the genetic association with speciﬁc SLE sub-phenotypes.12–15
These studies focused mainly on major histocompatibility
complex (MHC) class II genes, and found evidence that class II
alleles such as HLA-DRB1*03:01 are associated with auto-antibody
production.13 Our study substantially expands this work by not
only analysing imputed classical human leukocyte antigen
(HLA) alleles, but also examining variant HLA amino-acid
positions in conjunction with single-nucleotide polymorphism
(SNP) genotypes across the extended MHC region (chromosome 6:
26–34Mb). Our aim was to discover genetic loci within the
MHC region that are associated with speciﬁc clinical and/or
immunological manifestations within SLE cases and hence to
ﬁnd evidence of genetic variants that may drive speciﬁc forms
of the disease. For complex heterogeneous diseases such as SLE,
comprehensive sub-phenotype studies are critical in order
to understand how previously identiﬁed genetic associations
contribute to disease pathogenesis and speciﬁc disease
manifestations.
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RESULTS
Study sample
For this study, we collected genetic and sub-phenotype data from
3070 SLE cases of European descent characterized in four genetic
association studies of SLE. These SLE cases were previously
examined in a large meta-analysis that examined the association
between MHC genetic variation and SLE susceptibility.16 Table 1
describes the genotyping platform, number of genotyped MHC
SNPs, and sample size of each case collection in the study. Given
the strong genetic associations observed with anti-Ro/SSA and
anti-La/SSB autoantibody production described below, Table 1
also provides the frequency of these antibodies for each case
collection. Genetic (SNP) imputation was performed previously16
for each case collection, resulting in a total of 7119 SNPs common
between the four collections. In addition, classical HLA class I and
II alleles as well as their corresponding variant amino acids (AAs,
see Materials and Methods) were imputed and analysed.
Selection of sub-phenotypes for analysis
We examined the 11 ACR classiﬁcation criteria17 and 7 SLE-related
autoantibodies (anti-double-stranded DNA, anti-Sm, anti-RNP,
anti-Ro/SSA, anti-La/SSB, anti-cardiolipin IgG and anti-cardiolipin
IgM) as candidate sub-phenotypes for this study. Single-marker
associations for each candidate sub-phenotype with all variants
were assessed using logistic regression adjusted for population
substructure and case collection (Supplementary Table 1). We
analysed 7656 variants in total (7119 SNPs, 199 HLA alleles and
338 HLA amino-acid positions (see methods)). The speciﬁc
sub-phenotypes comprising anti-Ro and anti-La antibodies
demonstrated by far the most associations: 1635 and 1828
variants, respectively, at Po0.00001. For all other sub-phenotypes,
there were fewer than 30 variants that were signiﬁcant at this
level. Thus, we targeted anti-Ro and anti-La antibody subsets for
detailed investigation as they have the strongest evidence for a
genetic aetiology.
Anti-Ro antibody sub-phenotype
Stepwise conditional analysis. The most associated marker (in
terms of P-value as a single marker) was the class III SNP rs3129962
in BTNL2 (P¼ 9.47 10 27; odds ratio (OR)¼ 2.44, 95% con-
ﬁdence interval (CI)¼ 2.08–2.94; Table 2A). This marker is in
linkage disequilibrium (LD) with HLA-DRB1*03:01 (R2¼ 0.84,
D0 ¼ 0.99). When conditioning on this SNP as a covariate in
forward stepwise regression, the next most associated marker was
the class II SNP, rs9271731, between HLA-DRB1 and HLA-DQA1
(P¼ 9.56 10 07; OR¼ 1.54, 95% CI¼ 1.30–1.85). This SNP is in
LD with HLA-DRB1*15:01 (R2¼ 0.72, D0 ¼ 1). When using rs9271731
as an additional covariate, one further association signal was
detected at the class II SNP, rs3957146, between HLA-DQB1 and
HLA-DQA2 (P¼ 5.70 10 06; OR¼ 0.52, 95% CI¼ 0.39–0.69). Of
note, the effect sizes (ORs) and P-values that we present here are
estimated from the multivariate models returned by stepwise
regression (columns 2–3 in Table 2). The association results for a
given variant from single marker analyses can be seen in the last
two columns of Table 2.
The most associated amino acid (AA) was at position 77 in HLA-
DRB1 with the common AA threonine having a protective effect
(P¼ 2.72 10 13; OR¼ 0.49; 95% CI¼ 0.41–0.60). HLA-DRB1*03:01
and HLA-DRB1*03:02 encode the single alternative AA, asparagine,
(R2¼ 1). HLA-DRB1*03:02 is not signiﬁcantly associated with this
sub-phenotype (P¼ 0.37) possibly because of this allele being rare
(frequency of 0.01% in our data). We cannot be certain that this
lack of association applies to the general population and this needs
to be investigated to address this uncertainty. All other HLA-DRB1
alleles code for threonine. The single marker P-value for this AA
was very close to that of the most strongly associated SNP (see last
column in Table 2). Therefore, we ran a stepwise regression starting
from this marker. When conditioning on this AA, the next most
associated marker was the class II SNP, rs9271731, between
HLA-DRB1 and HLA-DQA1 (P¼ 4.5 10 08; OR¼ 1.63, 95%
CI¼ 1.37–1.95). When using rs9271731 as an additional covariate,
one further association signal was detected at the class III SNP,
rs3130781, in DPCR1 (P¼ 1.76 10 05; OR¼ 1.44, 95% CI¼ 1.22–
1.71). The SNP rs3130781 is in LD with HLA-DRB1*03:01 (R2¼ 0.29,
D0 ¼ 0.64) and HLA-B*08:01 (R2¼ 0.29, D0 ¼ 0.72). One ﬁnal associa-
tion signal was detected at HLA-DQB1*03:02 (P¼ 2.49 10 05;
OR¼ 0.56, 95% CI¼ 0.42–0.73). The results from this analysis can
be seen in Table 2B.
Owing to the correlation between the most associated SNPs
with known associated HLA-DRB1 alleles (rs3129962 tags HLA-
DRB1*03:01/Thr77 in DRB1 (R2¼ 0.84); rs9271731 tags HLA-
DRB1*15:01), we performed stepwise regression conditioning on
these HLA alleles as covariates. When conditioning on HLA-
DRB1*03:01 and HLA-DRB1*15:01, the next most associated marker
(rs9275582) was in class II between HLA-DQB1-HLA-DQA2 (P¼ 2.99
 10 06; OR¼ 0.61; 95% CI¼ 0.5–0.76). The most signiﬁcant HLA
allele was HLA-DQB1*03:02, which is in LD with rs9275582
(R2¼ 0.29, D0 ¼ 0.80). These two sets of results can be seen in
Tables 2C and 2D. We note that HLA-DQB1*03:02 is in LD (R2¼ 0.58)
with rs3957146 (the third associated SNP in the ﬁrst stepwise
regression presented in Table 2).
A simple stepwise regression analysis including only AA variants
indicated associations with Thr77, Leu67 and Gln96 in HLA-DRB1
(Table 2E). The HLA-DRB1 AA glutamine at position 96 is in LD with
HLA-DRB1*15:01 (R2¼ 0.82, D0 ¼ 1.00).
Model choice using the bayesian information criterion (BIC). Owing
to the extended LD, an analysis of the MHC using stepwise
regression to ﬁnd evidence for multiple independently associated
variants can lead to many models depending on the ﬁrst marker
conditioned on (used as a covariate for further association
analysis). This was discussed previously16 and here we also used
the BIC as an aid to model choice; the lower the BIC, the better
ﬁt the model is to the data (see methods). In our analysis of
sub-phenotype data, there was not much difference between
models A, C, D and E in Table 2 in terms of the BIC, which
represents the relative belief in a model given the data. However,
model B, which began the forward stepwise regression with
threonine at position 77 in HLA-DRB1, had the lowest BIC. This
model does have one more term than the other four models. Our
Table 1. Individual studies with number of genotyped SNPs, number
of SLE cases and sample sizes for anti-Ro/La within cases
Study case collection N
genotyped
MHC SNPsa
N
casesb
Sample sizes
(þ / /missing)
Illumina
HumanHap5506
2380 1123 Anti-Ro: 319/796/8
anti-La: 137/978/8
Illumina
HumanHap3175
1522 398 Anti-Ro: 36/107/225
anti-La: 17/126/255
Illumina Combined
MHC panel26
2360 917 Anti-Ro:158/454/
305
anti-La:79/531/307
Illumina custom
panel27
1230 632 Anti-Ro: 168/446/18
anti-La: 48/565/19
Abbreviations: MHC, major histocompatibility complex; SLE, systemic lupus
erythematosus; SNP, single-nucleotide polymorphism. The last column
denotes the number of SLE cases who were positive, negative or had
missing data for each sub-phenotype. aNumber of SNPs on the genotyping
platform located on chromosome 6 between 26 000 and 34 000 kb. bSee
original paper16 for a description of SLE case recruitment.
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extended model search (see methods) did not result in a model
with a lower BIC.
Haplotype analysis. There are two main extended MHC haplotypes
associated with SLE in northern Europeans that contain the
class II alleles HLA-DRB1*03:01 and HLA-DRB1*15:01.18 These
extended haplotypes are comprised of the following HLA alleles:
HLA-A*03:01—HLA-B*07:02—HLA-C*07:02—HLA-DRB1*15:01—HLA-D
QA1*01:02—HLA-DQB1*06:02 and HLA-A*01:01—HLA-B*08:01—HLA-
C*07:01—HLA-DRB1*03:01—HLA-DQA1*05:01—HLA-DQB1*02:01. We
tested for association of these extended haplotypes with anti-Ro
antibody status with the hypothesis that the association signals at
HLA-DRB1*03:01 and HLA-DRB1*15:01 are independent of these
haplotypes. We observed signiﬁcant effects for both haplotypes
(HLA-DRB1*03:01: P¼ 1.02 10 12, OR¼ 2.17; HLA-DRB1*15:01:
P¼ 0.02, OR¼ 1.71). We found evidence that HLA-DRB1*03:01 is
associated independently of the HLA-B*08:01-DRB1*03:01 haplotypic
background (P¼ 3.05 10 07), whereas we fail to ﬁnd evidence that
HLA-DRB1*15:01 (P¼ 0.17) is independent of the HLA-B*07:02-
DRB1*15:01 haplotype.
Anti-La antibody subphenotype
Stepwise conditional analysis. The most strongly associated marker
with the anti-La autoantibody sub-phenotype was the SNP
rs2894254, in the class III region (P¼ 3.40 10 30; OR¼ 3.38, 95%
CI¼ 2.74–4.16). This SNP is in LD (R2¼ 0.84, D0 ¼ 0.99) with HLA-
DRB1*03:01. We do not ﬁnd further associations when conditioning
on this SNP as a covariate. However, if we condition on HLA-
DRB1*03:01, we ﬁnd a further association with rs9268832, located
between HLA-DRA and HLA-DRB5 in class II (P¼ 6.53 10 06;
OR¼ 1.64; 95% CI¼ 1.32–2.04). Results from these two models can
be seen in Table 3. The HLA-DRB1 AA threonine at position 77 was
observed to have a protective effect, consistent with the anti-Ro
analyses. However, this AA was not the most associated marker
(P¼ 2.4 10 28). Conditioning on Thr77, we ﬁnd an additional
association with rs2227139, located in HLA-DRA in class II (P¼ 6.47
 10 06; OR¼ 1.64; 95% CI¼ 1.32–2.04). The SNP, rs2227139, is in
LD with rs9268832 (R2¼ 0.91, D0 ¼ 0.96).
Model choice using the BIC. As with the analysis of anti-Ro, we
used the BIC as an aid to model comparison. The model including
AA variation has the lowest BIC (model C in Table 3) but is only
slightly lower than the model conditioning on HLA-DRB1*03:01.
Therefore, we cannot choose between the AA and the HLA allele
as the best explanation for the data; however, conditional on
either of these we ﬁnd an independent association in class II. Both
of these models have a lower BIC than model A, which only has
the single most associated SNP (rs2894254). These data therefore
favour two independent associations in class II, one of which is
most likely HLA-DRB1*03:01 or the HLA-DRB1 AA threonine at
position 77. Our extended model search (see methods) returned
the same models as in Table 3.
Haplotype analysis. We observed signiﬁcant effects for the HLA-
DRB1*03:01 haplotype but not the HLA-DRB1*15:01 haplotype with
anti-La antibody status (HLA-DRB1*03:01: P¼ 1.19 10 16,
OR¼ 3.12; HLA-DRB1*15:01: P¼ 0.63). We found evidence that
HLA-DRB1*03:01 is associated independently of the HLA-B*08:01-
DRB1*03:01 haplotype (P¼ 6.42 10 13).
Independence of anti-Ro and anti-La autoantibody associations
with HLA-DRB1*03:01
Thus far, we have observed strong evidence of association
between HLA-DRB1*03:01 and both anti-Ro and anti-La autoanti-
body subsets. As these two phenotypes are correlated (R2¼ 0.27),
we performed conditional analyses to determine whether the
Table 2. Forward stepwise regression models for anti-Ro
Marker Estimates from the multiple regression model Single marker
OR (95% CI) P-value Class Gene OR (95% CI) P-value
(A) Forward stepwise regression (BIC¼ 2826.1)
rs3129962 (AoG) 2.44 (2.08–2.94) 9.47 10 27 Class III BTNL2 2.32 (1.98–2.71) 2.02 10 25
rs9271731 (AoG) 1.54 (1.30–1.85) 9.56 10 07 Class II DRB1-DQA1 1.27 (1.09–1.49) 2.58 10 03
rs3957146 (GoA) 0.52 (0.39–0.69) 5.70 10 06 Class II DQB1-DQA2 0.38 (0.29–0.50) 3.10 10 12
(B) Forward stepwise regression beginning from Thr77 DRB1 (BIC¼ 2815.9)
Thr77 DRB1 0.49 (0.41–0.60) 2.72 10 13 Class II DRB1 0.45 (0.39–0.52) 5.26 10 25
rs9271731 (AoG) 1.63 (1.37–1.95) 4.50 10 08 Class II DRB1-DQA1 1.27 (1.09–1.49) 2.58 10 03
rs3130781 (GoA) 1.44 (1.22–1.71) 1.76 10 05 Class III DPCR1 1.95 (1.69–2..25) 2.19 10 20
HLA-DQB1*03:02 0.56 (0.42–0.73) 2.49 10 05 Class II DQA1 0.42 (0.33–0.55) 1.67 10 10
(C) Forward stepwise regression conditioning on HLA-DRB1*03:01þHLA-DRB1*15:01 (BIC¼ 2829.8)
HLA-DRB1*03:01 2.22 (1.88–2.66) 1.11 10 20 Class II DRB1 2.22 (1.91–2.59) 9.29 10 25
HLA-DRB1*15:01 1.54 (1.28–1.85) 4.11 10 06 Class II DRB1 1.32 (1.13–1.57) 7.42 10 04
rs9275582 (AoG) 0.61 (0.50–0.75) 2.99 10 06 Class II DQB1-DQA2 0.45 (0.38–0.55) 6.12 10 16
(D) Forward stepwise regression analysing HLA alleles only (BIC¼ 2829.6)
HLA-DRB1*03:01 2.38 (2.02–2.80) 1.21 10 25 Class II DRB1 2.22 (1.91–2.59) 9.29 10 25
HLA-DRB1*15:01 1.63 (1.36–1.95) 9.71 10 08 Class II DRB1 1.32 (1.13–1.57) 7.42 10 04
HLA-DQB1*03:02 0.53 (0.41–0.70) 4.84 10 06 Class II DQB1 0.42 (0.33–0.55) 1.67 10 10
(E)Forward stepwise regression analysing amino acid data only (BIC¼ 2827.2)
Thr77 DRB1 0.29 (0.24–0.36) 4.00 10 32 Class II DRB1 0.45 (0.39–0.52) 5.26 10 25
Leu67 DRB1 0.64 (0.53–0.77) 2.81 10 06 Class II DRB1 1.05 (0.93–1.20) 4.22 10 01
Gln96 DRB1 1.47 (1.23–1.76) 2.29 10 05 Class II DRB1 1.29 (1.11–1.51) 1.28 10 03
Abbreviations: BIC, bayesian information criterion; CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio; SNP, single-nucleotide
polymorphism. SNPs have their minor and major alleles noted in brackets (AoG where A is the minor allele, for example), the OR is with respect to the minor
allele. For BIC see Materials and Methods.
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associations for each sub-phenotype were independent of each
other. We performed logistic regression analysis with each
sub-phenotype as an outcome and the other sub-phenotype as
a covariate. Table 4 displays the sample sizes and HLA-DRB1*03:01
frequencies for these case only analyses.
When conditioning on anti-La as a covariate, HLA-DRB1*03:01
continues to be strongly associated with anti-Ro antibody status
(P¼ 1.23 10 07, OR¼ 1.60 95% CI¼ 1.02–2.54). Also, when
conditioning on anti-Ro, HLA-DRB1*03:01 continues to be strongly
associated with anti-La antibody status (P¼ 1.66 10 12,
OR¼ 2.57 95% CI¼ 1.98–3.34). To assess the robustness of these
conditional regression results, we examined the anti-Ro associa-
tion in only anti-La-negative cases and found that HLA-DRB1*03:01
was still strongly associated with anti-Ro (P¼ 6.79 10 07,
OR¼ 1.58 95% CI¼ 1.32–1.89). In anti-La antibody-positive SLE
cases, HLA-DRB1*03:01 is weakly associated with anti-Ro
(P¼ 0.055, OR¼ 2.37 95% CI¼ 0.98–5.74). We performed the same
analyses for the anti-La antibody subset, stratifying on the anti-Ro
phenotype. In anti-Ro-positive SLE cases, HLA-DRB1*03:01 is
strongly associated with anti-La (P¼ 6.18 10 12, OR¼ 2.81
95% CI¼ 2.09–3.77). Among anti-Ro-negative SLE cases, HLA-
DRB1*03:01 is weakly associated with anti-La (P¼ 0.06, OR¼ 1.96
95% CI¼ 0.97–3.73). Therefore, we conclude that the association
signal for HLA-DRB1*03:01 with anti-La is not due to this sub-
phenotype’s correlation with anti-Ro, and vice-versa.
The HLA-DRB1*03:01 association with SLE susceptibility is
independent of the association with anti-Ro and anti-La antibody
subsets
We have provided strong evidence for the association between
HLA-DRB1*03:01 and both anti-Ro and anti-La antibody subsets. This
HLA-DRB1 allele has been consistently and strongly associated with
SLE susceptibility in European populations,16 and this is conﬁrmed
in our current data (P¼ 3.38 10 49; OR¼ 1.86 95% CI¼ 1.71–
2.02). However, the association of HLA-DRB1*03:01 with anti-Ro/anti-
La antibody subsets and SLE susceptibility may not be
independent—the DRB1*03:01 association with SLE may be purely
secondary to its association with anti-Ro and anti-La antibody status.
If the association between HLA-DRB1*03:01 and SLE status is not
driven entirely by sub-phenotype then one could hypothesize a
three-level model of disease type (unaffected; sub-phenotype-
negative case; sub-phenotype-positive case) based on increasing
HLA-DRB1*03:01 frequency. Figure 1 plots the change in HLA-
DRB1*03:01 dosage over levels of disease; the average dosage
appears to increase over all three levels. Therefore, we examined
(see methods) the hypothesis that the HLA-DRB1*03:01 association
with anti-Ro and anti-La antibody sub-phenotypes explains the
association of DRB1*03:01 with SLE in general. We also tested
whether the risk was additive over the three levels of disease.
Anti-Ro antibody sub-phenotype
We found a signiﬁcant difference in HLA-DRB1*03:01 dosage
between healthy controls and anti-Ro antibody negative cases
(P¼ 1.97 10 14). The estimated change in dosage was 0.1 (95%
CI¼ 0.08–0.13), equivalent to a change in allele frequency of 0.05
(95% CI¼ 0.04–0.06).
We also found a signiﬁcant increase in dosage between anti-Ro-
negative cases and anti-Ro positive cases (P¼ 2.97 10 33). The
estimated change in dosage (see Table 5) is 0.27 (95% CI¼ 0.22–0.31),
equivalent to a change in frequency of 0.13 (95% CI¼ 0.11–0.16).
We found evidence against the hypothesis that the increase in
dosage is additive over the three disease levels (P¼ 0.008). Our
ﬁnal test against the additive model implies that the difference in
HLA-DRB1*03:01 dosage between anti-Ro( )/anti-Ro(þ ) status
(increase of 0.27) in the cases is more than double that of the
difference between cases and healthy controls (increase of 0.10).
Anti-La antibody subphenotype
We found a signiﬁcant difference in HLA-DRB1*03:01 dosage
between healthy controls and anti-La-negative cases (P¼ 3.57
 10 25). The estimated change (see Table 5) in dosage is 0.13
(95% CI¼ 0.11–0.15), equivalent to a change in frequency of 0.06
(95% CI¼ 0.05–0.08).
We also found a signiﬁcant increase in dosage between anti-La-
negative and anti-La-positive cases (P¼ 2.45 10 39). The
estimated change in dosage (see Table 5) is 0.41 (95%
CI¼ 0.35–0.47), equivalent to a change in frequency of 0.21
(95% CI¼ 0.18–0.24).
We found evidence against the hypothesis that the increase in
dosage is additive over the three disease levels (P¼ 1.5 10 04).
Table 4. Allele frequencies for HLA-DRB1*03:01 in case only association
analysis of anti-Ro and anti-LA when conditioning on the status of
each sub-phenotype
Status Anti-La(þ ), N Anti-La( ), N
Anti-Ro(þ ) 0.41 (259) 0.26 (418)
Anti-Ro( ) 0.28 (22) 0.18 (1781)
Frequencies for the HLA-DRB1*03:01 allele are shown with the sample sizes
in brackets.
Table 3. Forward stepwise regression models for anti-La
Marker Estimates from the multiple regression model Single marker
OR 95% CI P-value Class Gene OR P-value
(A) Forward stepwise regression (BIC¼ 1677.92)
rs2894254 (CoA) 3.38 2.74–4.16 3.40 10 30 Class III c6orf10—BTNL2 3.38 3.40 10 30
(B) Conditional on HLA-DRB1*03:01 as a covariate (BIC¼ 1673.31)
HLA-DRB1*03:01 2.50 2.00–3.13 1.40 10 15 HLA-DRB1 3.15 3.31 10 28
rs9268832 (CoA) 1.64 1.32–2.04 6.53 10 06 Class II DRA-DRB5 2.31 2.46 10 17
(C) Forward stepwise regression starting from AA-DRB1*77T (BIC¼ 1672.53)
Thr77 DRB1 0.40 0.32–0.50 1.33 10 15 HLA-DRB1 0.32 2.40 10 28
rs2227139 (CoA) 1.64 1.32–2.04 6.47 10 06 Class II HLA-DRA 2.32 1.86 10 17
Abbreviations: BIC, bayesian information criterion; CI, confidence interval; OR, odds ratio.SNPs have their minor and major alleles noted in brackets (AoG
where A is the minor allele, for example), the OR is with respect to the minor allele. For BIC see Materials and Methods.
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Table 5 displays the effect sizes and P-values for this analysis. Our
ﬁnal test against the additive model implies that the difference in
HLA-DRB1*03:01 dosage between anti-La( )/anti-La(þ ) status
(increase of 0.41) in the cases is more than triple that of the
difference between cases and healthy controls (increase of 0.13).
Double positive and double negative anti-Ro and anti-La antibody
sub-phenotypes
Our study was large enough to determine whether the frequency
of HLA-DRB1*03:01 differs between SLE cases who are double
negative for anti-Ro and anti-La antibodies (N¼ 1781) and healthy
controls (N¼ 9782). It is known that these antibodies are present
in approximately 2% of the healthy population; however, we do
not have this phenotype data for the controls. The following
results therefore assume that all controls are negative for
antinuclear antibodies. We found a signiﬁcant association of
HLA-DRB1*03:01 with the double negative SLE cases/healthy
controls status (OR¼ 1.49, 95% CI¼ 1.35–1.65; P¼ 2.23 10 14).
Further analysis demonstrated a stronger association with the
double positive (n¼ 259)/double negative SLE case status
(OR¼ 3.71, 95% CI¼ 2.97–4.64; P¼ 2.00 10 16). To test whether
these two odds ratios differ, we ran the same analysis for a three-
stage risk model as we did for anti-Ro and anti-La antibody
subsets separately (see above, Table 5 results). We found very
strong evidence against the hypothesis that the increase in
dosage is additive over the three disease levels (P¼ 6.65 10 06).
The non-additive effect leads to a very large odds ratio between
double positive SLE cases and healthy controls, which we found to
be 5.27 (95% CI¼ 4.31–6.44; P¼ 3.14 10 59; Figure 1).
DISCUSSION
Our results conﬁrm, in the largest SLE sub-phenotype genetic
association study to date, that the often replicated genetic
association at HLA-DRB1*03:01 does not just inﬂuence SLE
susceptibility but is also associated with anti-Ro and anti-La
autoantibody production. For the ﬁrst time, we have shown that
HLA-DRB1*03:01 is associated with SLE per se, independent of
anti-Ro and anti-La antibody subsets. These data implicate HLA-
DRB1*03:01 and variants in LD with it in the predisposition to anti-
Ro and anti-La autoantibody production as well as processes
outside of this manifestation.
We do not ﬁnd conclusive evidence that variant HLA AAs
explain the majority of the MHC association signal in anti-Ro
and anti-La autoantibody subsets in SLE. This is largely due to
the confounding effects of extended LD displayed by the
associated DRB1*03:01 and to a lesser extent, the DRB1*15:01
haplotypes in our study cohorts. These results contrast with
those of a recent study in anti-CCP-positive rheumatoid
arthritis, where ﬁve HLA AA variants were suggested to largely
explain the MHC association with disease status.19 In this case,
the disease-associated variants generally reside on a diversity
of haplotypes. Studies in other autoimmune/inﬂammatory
diseases have either not shown robust association signals with
variant HLA AA data or like the present study have shown
association with AAs in strong LD with previously associated HLA
alleles. It may be that HLA amino association signals are more
complex than the single-variant testing method we and others
have used.
Limitations of the present study include the heterogeneity
in autoantibody testing procedures and sub-phenotype data
collection between the four studies. As a result, data were
tabulated and analysed in an essentially binary format (that is,
individual cases were classiﬁed as positive, negative or missing
for each trait), to allow meta-analysis. However, in so doing, a
degree of noise is inevitable, which would reduce our power to
detect true association signals particularly in the less common
sub-phenotypes. We were also limited by the imputation required
to analyse a consistent set of SNPs across studies and the
reliance on HLA imputation. In addition, we are constrained
in our conclusions on differences in results for anti-Ro and
Figure 1. HLA-DRB1*03:01 dosage (average number of alleles observed) over levels of disease (a): (healthy controls/anti-Ro( )/anti-Ro(þ )); (b):
(healthy controls/anti-La( )/anti-La(þ )); (c) (healthy controls/anti-Ro( ) AND anti-La( )/anti-Ro(þ ) AND anti-La(þ )/). Average dosage is
represented by a square, whereas upper and lower 95% confidence intervals are represented by ‘ ’. Note that dosage ranges from 0 to 2 for
each subject and so to convert to allele frequency you must divide by 2. All three plots have been truncated at 1.
Table 5. Multi-level model for HLA-DRB1*03:01 dosage over
phenotype
Phenotype Effect
(change in
dosage)
95% CI P-value
(A) Results for anti-Ro
Anti-Ro( )/control 0.10 0.08–0.13 1.97 10 14
Anti-Ro(þ )/anti-Ro( ) 0.27 0.22–0.31 2.97 10 33
(B) Results for anti-La
Anti-La( )/control 0.13 0.11–0.15 3.57 10 25
Anti-La(þ )/anti-La( ) 0.41 0.35–0.47 2.45 10 39
Abbreviation: CI, confidence interval. Effect is the change in dosage for
HLA-DRB1*03:01 between positive and negative for specified phenotype.
(A) Results for healthy control/anti-Ro-negative/anti-Ro-positive. (B) Results
healthy control/anti-La-negative/anti-La-positive.
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anti-La antibody subsets given the much smaller sample size
available for the anti-La phenotype. Thus, we have conﬁned
some of our analyses to the most robust association; that of
HLA-DRB1*03:01 with both anti-Ro and anti-La antibody
sub-phenotypes. We must also allow for the possibility that
associations with HLA-DRB1*03:01 could exist with other SLE
subsets that overlap with anti-Ro/La, but have not been detected
in our study. This highlights the need for extension of this work to
other cohorts with sub-phenotype data in order to increase
sample size and power across as wide a range of phenotypes as
possible.
In both anti-Ro and anti-La sub-phenotypes, we ﬁnd evidence
of secondary independent associations in the class II region of the
MHC after conditioning on HLA-DRB1*03:01, and we ﬁnd
additional signals in class II and class III for anti-Ro. We have
shown that the association of HLA-DRB1*03:01 with anti-Ro
antibody status is independent of the association with anti-La
and vice-versa. We have also shown that the association between
SLE case/healthy control and HLA-DRB1*03:01 is not purely due to
the association with anti-Ro and anti-La antibody sub-phenotypes.
This implies a three-level model of risk for increasing dosage of
HLA-DRB1*03:01, where the frequency of this allele is higher in
anti-Ro-negative cases than in healthy controls and higher still in
anti-Ro-positive cases than anti-Ro-negative cases. The same is
true for anti-La. In fact, we ﬁnd very strong evidence that the
HLA-DRB1*03:01 risk of anti-Ro/anti-La double positive within SLE
patients is much greater than the risk of anti-Ro/anti-La double
negative (other lupus phenotypes without these anti-bodies
present) in the general population. We can conclude that
the association of HLA-DRB1*03:01 with SLE is driven to a large
extent but not entirely by anti-Ro and anti-La auto-antibody
sub-phenotypes.
Although we do ﬁnd evidence of an independent class III
association with anti-Ro, there is some uncertainty. We ﬁnd a
signiﬁcant association with the class III SNP rs3130781 conditional
on the AA Thr77-DRB1. However, when conditioning on the
markers in model C in Table 2 (HLA-DRB1*03:01þHLA-
DRB1*15:01þ rs9275582; BIC¼ 2829.8) in a forward stepwise
regression, the association with rs3130781 is not signiﬁcant
(P¼ 4.2 10 05). This is also the case for model D in Table 2
(HLA-DRB1*03:01þHLA-DRB1*15:01þHLA-DQB*03:02; BIC¼ 2829.6).
So conditional on HLA-DRB1*03:01 and HLA-DRB1*15:01, we ﬁnd an
independent association in class II but not class III. However, we did
consider conditioning on HLA-DRB1*03:01 alone, where a stepwise
regression returned a class II SNP (rs9271731; R2 with HLA-
DRB1*15:01¼ 0.72) and the class III SNP rs3130781. This model has
a BIC¼ 2929.00. Hence, there is uncertainty as to whether there is an
independent class III effect when conditioning on HLA-DRB1*03:01; all
three models ﬁt the data equally well (not much difference in the
BIC). Nevertheless, the best model in Table 2 does suggest that there
is an independent class III effect conditional on the class II AA Thr77-
DRB1. This model has a much lower BIC than any others. There is
some evidence, therefore, of a class III association with anti-Ro;
however, we believe that more data, and ideally across diverse
populations (to help remove effects due to LD), are required to be
more deﬁnitive about this.
The results of the present study while enlightening are
confounded by the strong and extended LD present on the
principally associated HLA-DRB1*03:01 and HLA-DRB1*15:01
haplotypes. Complementary studies in accurately phenotyped
southern European and non-European SLE cohorts, which show
haplotypic diversity at the MHC, will allow reﬁnement of the
sub-phenotype association signals found in the predominantly
northern European populations studied thus far.20 These
efforts may still yield association intervals that harbour several
genes/variants. Therefore, future work will inevitably require
re-sequencing, transcriptomic and epigenetic studies in order to
tease out these complex association signals.
MATERIALS AND METHODS
Study design
This study is a meta-analysis of four studies taken from work described in a
previous paper.16 We only included four of the six previous studies in this
work as sub-phenotype data were not available from the other two studies
(named ‘Affy500K’ and ‘Affy100K’ in the previous paper). We refer to the
previous meta-analysis of SLE case–control data as the ‘parent study’ in this
work. The number of SLE cases and controls in this paper for the four
included studies are the same as in the parent study, and quality control
(QC) procedures for these data are described in full in the previous paper,
including tests for relatedness and adjustments for population structure.
We include some QC descriptions below for clarity in this paper.
QC and imputation
SNPs. We only analysed SNPs that passed QC in our previous paper,16
which utilized these data: 90% genotyping for all subjects and SNPs, minor
allele frequency 40.01 and Hardy–Weinberg equilibrium (false discovery
rate of 0.05).
HLA imputation. We imputed HLA genotypes using HLA*IMP V2.21 Only
genotyped SNPs in each case collection were used for this imputation. We
used posterior probabilities of HLA genotypes, rather than most likely
genotypes, in order to allow for uncertainty in imputation. From these
probabilities, we calculated dosages for each allele (expected number of
alleles 0oxo2). We had HLA-DRB1 typed data in two studies: the ‘Illumina
Combined MHC panel’ study (N¼ 1608) and the ‘Illumina Custom panel’
study (N¼ 605). This allowed for assessment of accuracy, which for the two
main reported positive associations in this paper were as follows: for
HLA-DRB1*03:01, we achieved sensitivity of 0.992/0.999 and speciﬁcity of
0.995/0.993 for the Illumina Combined MHC panel and Illumina Custom
panel’ respectively. For HLA-DRB1*15:01, we achieved sensitivity of 0.980/
0.992 and speciﬁcity of 0.996/0.997.
AA translation
AA sequences for each HLA allele were extracted from the European
Bioinformatics Institute HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/).
HLA allele dosages were converted to AA dosages at each position; the
dosage for a particular amino acid ‘A’ at position ‘p’ would be the sum of
HLA alleles’ dosage that coded for amino acid ‘A’ at position ‘p’. The total
dosage for each position is therefore equal to 2 and this total is split
between each possible AA at the position.
We had data at 338 AA positions that had variable AAs (HLA-A¼ 67,
HLA-B¼ 75, HLA-C¼ 71, HLA-DPB1¼ 21, HLA-DQA1¼ 41, HLA-DQB1¼ 61,
HLA-DRB1¼ 52). Owing to multiple possible AAs at each position, we
actually had 1255 possible position/AA variants in total.
Adjustment for population structure. We analysed the data with the
statistical computing language R22 using logistic regression. All analyses
were adjusted for ancestry utilizing the ﬁrst principal component (PC) or
percentage of northern European ancestry, as previously described16 and
included a covariate for project. As the PCs were computed speciﬁcally for
each case collection, we also included interaction terms between projects
and ancestry to allow for different effect sizes in the adjustment for
population structure.
Single-marker analysis of candidate sub-phenotypes and analysis of SLE as a
simple disease outcome. We examined the 11 ACR criteria17 and presence
of 7 SLE-related auto-antibodies (anti-Ro/SSA, anti-La/SSB, anti-double-
stranded DNA, anti-RNP, anti-Sm and anticardiolipin IgG and IgM) as
candidate sub-phenotypes for detailed analysis. To determine which sub-
phenotypes were most strongly inﬂuenced by genetic variation in the
MHC, we tested each sub-phenotype for association with all variants (SNPs,
HLA alleles and HLA AAs) in single-variant association tests using logistic
regression adjusted for population substructure and case collection. We
also tested the association between markers and SLE as a simple disease
outcome for the four studies considered here. Results for association with
HLA-DRB1*03:01 are discussed in the beginning of the section titled ‘The
HLA-DRB1*03:01 association with SLE susceptibility is independent of the
association with anti-Ro and anti-La antibody subsets’.
Conditional association analysis of anti-Ro and anti-La. Owing to
numerous single-marker associations within the extended LD of the
MHC, we used conditional analyses to narrow these associations to those
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with the best evidence for strength and independence. All analyses utilized
logistic regression with ancestry and project covariates (see above) and
were halted when the evidence for association with a new term was
P43 10 05. We performed classic forward stepwise regression,
conditioning on the top variant to ﬁnd the second variant, and so on.
A simple forward stepwise approach can lead to over-ﬁtting (selecting
many correlated markers) and the results may be misleading because of
selected markers potentially tagging two or more independently
associated markers.16 Therefore, we also performed a model search
using the BIC16 as the inclusion metric in a stepwise regression using the
R22 ‘step()’ function, ﬁrst starting with no prior model (other than
covariates above) and also starting from HLA-DRB1*03:01 and HLA-
DRB1*15:01 as initial model terms. Although BIC optimization was used
to select model terms, we terminated the selection when it would result in
a term with P43 10–5. The BIC23,24 is a penalized likelihood model choice
criterion similar to the Akaike Information Criterion24 except there is a
stronger penalty for additional model parameters that increases with
sample size. The BIC is therefore more conservative and favours smaller
models than the Akaike Information Criterion. As with the Akaike
Information Criterion, the smaller the BIC the better the model is judged
to ﬁt the data.
Haplotype analysis of anti-Ro and anti-La. Given the high degree of
correlation between the associated variants identiﬁed from the model
searches described above, we conducted a haplotype analysis of these
variants using PLINK25 using the best-guess genotypes estimated from
HLA*IMP2. We used PLINK to phase haplotypes and perform multivariate
logistic regression where terms are haplotypes rather than individual
variants, optionally controlling for individual variants or haplotypes.
Multiple testing. In the MHC, a Bonferroni adjustment for multiple testing
is inappropriate because of the extensive LD and hence correlated variants.
In order to determine the number of independent variants, we performed
a PC analysis of all SNPs. In our data, we found that 374 PCs had
eigenvalues 41 and these PCs explained 96% of the variance. Thus, we
used a multiple-testing threshold of Po0.01/374¼ 3 10 5.
Testing for independence between the SLE association and sub-phenotype
association with HLA-DRB1*03:01. We ﬁtted a linear regression model with
dosage for HLA-DRB1*03:01 as the outcome and both case/control status
and sub-phenotype status as explanatory variables. We therefore tested
each effect conditional on the other. A signiﬁcant association for case/
control status conditional on sub-phenotype implies that we reject the
hypothesis that sub-phenotype is solely driving the case/control associa-
tion. This is equivalent to setting the three-level status as a factor in the
regression in terms of model ﬁt. But rather than obtaining an estimate of
dosage change between healthy controls and sub-phenotype positive as
we would in a three-level factor (where the baseline is healthy control), we
get an estimate of change between sub-phenotype positive and sub-
phenotype negative. In both models, we also get an estimate of change
between healthy controls and sub-phenotype negative.
Furthermore, we tested the hypothesis that the increase in dosage is
additive over the three disease levels (Healthy-Control Case sub-
phenotype negative/Case sub-phenotype positive). This is achieved by
ﬁtting a model with an additive effect for dosage over the three phenotype
levels. This additive model is nested within our model used to test
independence of sub-phenotype association with SLE-case/healthy con-
trol, so we performed a likelihood ratio test. A rejection of this additive
model, in favour of the three-level factor model (described in the previous
paragraph), is evidence that the change in dosage over sub-phenotype
within cases is different than the change in dosage between healthy
controls and SLE without the sub-phenotype.
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